Revalia Bio Revenue

About Revalia Bio

Revalia Bio is a seed series start-up spun out of Yale with 20M funding, 30M government contracts, and 40M research grants. Revalia Bio is seeking to revolutionize biomedical innovation by creating the world's first integrated human data stack Revalia Bio is a forward-thinking digital health, tech startup building the world's first integrated human data stack to modernize biomedical innovation by enabling a new class of digitally enabled Phase 0 Human Trials. Revalia’s Phase 0 Human Trial platform integrates various sources of human data to ask and answer questions that are impossible with current Phase I/II clinical trials or preclinical models alone. The key to the platform is Revalia’s ‘Human Organ Data Layer’ made possible by a unique network of partnerships assembled to support organ donation for research when those organs are not suitable for clinical transplant. The Revalia team brings those organs back to life on proprietary organ perfusion technology to create a ‘Rosetta Stone’ for human data that serves to integrate and contextualize all other sources of human data from patient medical records to cells in a petri dish. Revalia provides access to the Phase 0 Human Trial through a Platform as a Service model that enables biomedical developers to design, track and interpret Phase 0 Human Trials at the click of a button guided by Rio, Revalia’s software companion. Through this new platform, Revalia aims to enable the global biomedical community—from academic scientists and hospitals to large biopharma—to effectively collaborate on creating better medicines faster. The team at Revalia believe that biomedical innovators should compete on delivering the best innovations to patients as fast as possible, not on access to critical human data.

View contact profiles from Revalia Bio